Document for the exclusive use of visitor(baader_unknow@alphavalue.eu)

Baader Helvea Equity Research

COMPANY FLASH

26 July 2021

HBM Healthcare Investments

Switzerland

Other financials

Reuters: HBMN.S	Bloomberg: HBMN SE
Add	
Closing price as of 23-Jul-21	CHF 339.00
Target price	CHF 355.00
High/Low (12M)	CHF 359.50/257.50
Market cap.	CHF mn 2,358
Enterprise value	CHF mn 2,404
Free float	83.0%
Avg. daily turnover	CHF mn 1.84

Price relative to Index



Performance (%)	1M	3M	6M
Absolute	-5.7	4.6	7.6
rel. SPI	-7.7	-3.6	-7.4
rel. STOXX Europe 600	-7.6	-0.5	-5.3
rel. SXXP Financial SVS	-11.5	-6.0	-8.2

Analyst: Bruno Bulic, Ph.D. +41 43 388 9225 bbulic@helvea.com

Private equities further boosting HBM results

Our conclusion

HBM Healthcare reported on Friday the results of its first quarter of the 2021/22 financial year with a profit of CHF 136mn, on a net asset value (NAV) increase by 6.3% while HBM Healthcare shares gained 6.9%, consolidating the premium to share price which reached 8.1% end-June 2021. HBM premium entered positive territory early 2021, following the excellent performance in 2020, thus reflecting investor's confidence in HBM strategic development. We note that the premium to price declined in recent weeks (2.1% as of 15 July 2021), offering in our eyes an attractive entry point for investors.

Baader

- During a quarter characterized by a sell-off in the healthcare sector, mostly due to expectations on Central Banks interest hikes, HBM Healthcare demonstrated the resilience of its business model largely supported by private equities, which contributed with CHF 90mn during the quarter. Three companies successfully went public: Werewolf Therapeutics, Ambrx Biopharma and Monte Rosa Therapeutics. In addition, Valo Health signed a merger agreement with listed company Khosla Ventures Acquisition Co. Swixx BioPharma, NiKang Therapeutics and ConnectRN completed financing rounds with external investors at higher valuations, and Tata Digital acquired a majority stake in leading Indian healthcare platform 1mg.
- Positive outlook: "The portfolio continues to be well diversified and finely balanced in terms of composition (private and public companies, geographical regions, stages of development and areas of activity or therapy). This reduces dependence on the development of individual sectors or regions within the healthcare market, which has a stabilizing effect and should continue to have a positive impact on performance.
- Essentially, nothing has changed compared to the outlook outlined in the annual report. The fundamental factors continue to speak for a successful development of the sector as a whole and for the portfolio companies individually. In this respect, the Company expects further value-enhancing events from its portfolio due to IPOs, financing rounds, company takeovers or clinical trial results.

Facts & Analysis

- The portfolio of other public companies contributed CHF 45mn to profit. This came mainly from the investments in the fast-growing Indian biopharmaceutical company Laurus Labs, the US company Biohaven Pharmaceuticals and the new investment in Hutchmed China. In addition to its listing on Nasdaq, Hutchmed China completed an IPO on the Hong Kong Stock Exchange during the quarter under review, with HBM Healthcare Investments participating as a cornerstone investor with USD 20mn.
- The market and currency hedges resulted in profit contributions of CHF 7mn and CHF 24mn, respectively. The market hedge was fully unwound in the quarter under review and the USD currency hedge was reduced to around 35 percent of the exposure. Other assets reduced the investment result by CHF 10mn, mainly due to currency fluctuations. (Source: HBM Healthcare communication)

Key financials

Key financials						Valuation ratios				
CHF mn	2019/20	2020/21E	2021/22E	2022/23E	CAGR (%)	x	2019/20	2020/21E	2021/22E	2022/23E
Sales	0.0	0.0	0.0	0.0	-	EV/Sales	-	-	-	-
EBIT adj.	185.1	691.5	172.5	279.5	14.7	EV/EBIT adj.	8.1	1.7	13.9	8.6
EPS adj. (CHF)	26.26	99.24	24.63	40.01	15.1	P/E adj.	7.7	1.7	13.8	8.5

Source: Company data, Baader Helvea Equity Research

Baader Helvea Equity Research

COMPANY FLASH

HBM Healthcare Investments

Key data

FY 31 Mar. 2017/9 2019/20 2020/22 2021/22 EPS sponder COFF) 16.55 30.05 28.26 99.24 24.63 Divideral (CHF) 16.55 30.05 28.26 99.24 24.63 Divideral (CHF) 16.53 30.05 28.26 99.24 24.63 Divideral (CHF) 16.53 30.05 28.25 303.91 332.20 Free cash flow (CHF) 18.12 7.06 8.03 1.153.6 2.285.64 Enterprise value (CHF mn) 864.9 1.139.8 1.406.3 1.153.6 2.385.4 Enterprise value (CHF mn) 864.9 1.270 T.7 T.3 1.38 PEW (M) 7.5 5.5 7.7 T.7 T.38 Divideral (pid) 5.6 4.6 3.8 6.6 1.0 ECFEV (M) 5.9 4.0 3.7 T.46 3.3 ECFEV (M) 5.6 4.6 3.8 6.6 1.0 EVERDA al.(M) - -	2022/23E
EPS adjusted (CHF) 16.55 30.05 72.26 92.44 Divident (CHF) 6.66 7.50 7.71 11.24 12.29 Dovident (CHF) 6.12 7.06 8.03 7.92 11.46 Arg. no. of shares (mn) 7.0 7.0 7.0 7.0 7.0 Market cap, (wg, Journet): (CHF mn) 884.9 1.139.8 1.405.3 1.155.5 2.358.4 Free dash (M CHF mn) 980.0 1.237.0 1.50.10 1.199.0 2.403.5 Valuation T 7.7 7.7 7.7 7.1 1.8.8 PCF M(G) 7.5 5.7 7.7 7.7 1.7 1.8.8 Divident yield (% (FCF/Mcp.) 6.6 4.3 4.0 4.8 3.4 Divident yield (% (FCF/Mcp.) 6.6 4.3 4.0 4.8 3.4 Divident yield (% (FCF/Mcp.) 5.8 4.6 3.8 1.1 7 13.9 EVERIT Ad. (c) 8.1 5.8 8.1 1.7 13.	
EPS adjusted (CHF) 16.55 30.05 22.26 99.24 24.63 Book value (CHF) 165.39 168.49 208.25 303.91 332.20 Book value (CHF) 8.12 7.08 8.03 7.22 11.46 Arg, no. of share (mr) 7.0 7.0 7.0 7.0 7.0 7.0 Market cap, (wg, our of share (mr) 980.0 1.237.0 1.501.0 1.198.0 2.358.4 Free cash (no. (CHF mr) 980.0 1.237.0 1.501.0 1.59.0 2.403.6 Valuation PE adj, (c) 7.5 5.7 7.7 1.7 1.8. P/EV (r) 0.7 0.9 1.0 0.5 1.0 Dividend (r)(CF/Map.) 6.6 4.3 4.0 4.8 3.4 Dividend (r)(S) (FC/Map.) 5.6 4.6 3.8 8.1 1.7 13.9 EVEBTDA adj, (c) 8.1 5.8 8.1 1.7 13.9 EVESTady, (c) 0.1 - - - - <td>40.01</td>	40.01
Divident (CHF) 6.96 7.50 7.71 11.24 12.29 Book value (CHF) 165.39 189.49 208.25 303.91 332.20 Free cash flow (CHF) 8.12 7.06 8.03 7.92 11.46 Arg. no. of shares (nn) 7.0	40.01
Book value (CHF) 166.39 189.49 202.25 303.91 332.20 Free cash flow (CHF) 8.12 7.06 8.03 7.92 7.0 7.	0.00
Free cash fow (CHF) 8.12 7.06 8.03 7.92 11.46 Arg. no. of shares (ma) 7.0	376.06
Avg. no. of shares (mn) 7.0 7.0 7.0 7.0 7.0 7.0 Market cap. (avg./current, CHF mn) 864.9 1,139.8 1,405.3 1,153.5 2,368.4 Enterprise value (CHF mn) 960.0 1,237.0 1,501.0 1,199.0 2,403.6 Valuation 7.5 5.5 7.7 1.7 13.8 P/E vd, (v) 0.7 0.9 1.0 0.5 1.0 FOF (V) 5.9 4.0 3.7 4.6 3.3 FOF (V) 5.6 4.6 3.8 6.8 3.6 EV/Set (X) 8.1 5.8 8.1 1.7 13.9 EV/Set (X) 8.1 5.8 8.1 1.7 13.9 EV/Set (X) 8.1 5.8 8.1 1.7 13.9 EV/Set (X) - - - - - Sates growth (%) - - - - - Sates growth (%) - - - <	12.51
Intervise value (CHF mn) 864.9 1,138.8 1,405.3 1,153.5 2,388.4 Enterprise value (CHF mn) 960.0 1,237.0 1,501.0 1,199.0 2,403.6 Valuation	7.0
Enterprise value (CHF mn) 960.0 1,237.0 1,501.0 1,199.0 2,403.6 Valuation 75 5.5 7.7 1.7 13.8 P/Bv (x) 0.7 0.9 1.0 0.5 1.0 CF/Ev (%) 5.9 4.0 3.7 4.6 3.3 FCF/Ev (%) 5.9 4.0 3.7 4.6 3.3 CF/Ev (%) 5.9 4.0 3.7 4.6 3.3 CVSates (x) - - - - - EV/EBT adj (%) 8.1 5.8 8.1 1.7 13.9 EV/EET adj (x) - - - - - CVEE (x) - - - - - Rey company data - - - - - Sates growth (%) -15.0 78.8 -12.5 273.5 -75.1 EBIT Ad di, growth 6%) -15.0 78.8 -12.5 - - - <t< td=""><td>2,358.4</td></t<>	2,358.4
Valuation PFE adj. (x) 7.5 5.5 7.7 1.7 13.8 P/BV (x) 0.7 0.9 1.0 0.5 1.0 FCF yiel (X) (FCF/Mcap.) 6.6 4.3 4.0 4.8 3.3 FCF yiel (X) (FCF/Mcap.) 6.6 4.3 4.0 4.8 3.4 Dividend yiel (%) 5.6 4.6 3.8 6.8 3.6 EV/Sales (X) - - - - - EV/EBITA ad, (A) 8.1 5.8 8.1 1.7 13.9 EV/EBITA ad, (A) 8.1 5.8 8.1 1.7 13.9 EV/EBITA ad, (A) 8.1 5.8 8.1 1.7 13.9 EV/EBITA ad, magn (M) - - - - - Rey company data - - - - - EBITDA ad, magn (%) - - - - - Fere cash flow margin (%) - - - - -	2,403.2
PFE a(r) 7.5 5.5 7.7 1.7 13.8 PBV (x) 0.7 0.9 1.0 0.5 1.0 PCF.EV (%) 5.9 4.0 3.7 4.6 3.3 FCF yild (%) (FCFMap.) 6.6 4.3 4.0 4.8 3.4 Dividend yild (%) 5.6 4.6 3.8 6.8 3.6 EV/Sales (x) - - - - - EV/EDT ad, (x) 8.1 5.8 8.1 1.7 13.9 EV/EDT ad, (x) 8.1 5.8 8.1 1.7 13.9 EV/EDT ad, (x) - - - - - CSC (x) -	2,100.2
PEW (n) 0.7 0.9 1.0 0.5 1.0 FCF yiel (%) 5.9 4.0 3.7 4.6 3.3 Dividend yield (%) 5.6 4.6 3.8 6.8 3.4 Dividend yield (%) 5.6 4.6 3.8 6.8 3.4 Dividend yield (%) 5.6 4.6 3.8 6.8 3.4 EVISates (x) - - - - - EVIEBITD adj. (x) 8.1 5.8 8.1 1.7 13.9 EVICE (x) - - - - - - ROCEWACC adj. (x) - - - - - - Sates growth (%) - <td>8.5</td>	8.5
FCF/EV (%) 5.9 4.0 3.7 4.6 3.3 FCF yield (%) (FCF/Mcap.) 6.6 4.3 4.0 4.8 3.4 Dividend yield (%) 5.6 4.6 3.8 6.8 3.6 EVSales (A) - - - - - - EVEBITDA adj. (A) 8.1 5.8 8.1 1.7 13.9 EVCEITDA adj. (A) 8.1 5.8 8.1 1.7 13.9 EVCEX (A) - - - - - - ROCEWACC adj. (A) - <	0.9
FCF yield (%) (FCF/Mcap.) 6.6 4.3 4.0 4.8 3.4 Dividend yield (%) 5.6 4.6 3.8 6.8 3.6 EVSates (x) - - - - - EVEEIDDA adj. (x) 8.1 5.8 8.1 1.7 13.9 EV/EENT adj. (x) 8.1 5.8 8.1 1.7 13.9 EV/EENT adj. (x) - - - - - ROCEWACC adj. (x) - - - - - Key company data - - - - - Sales growth (%) -15.0 76.8 -12.5 27.3.5 -7.5.1 EBITDA adj. growth (%) - - - - - Fee cash flow margin (%) - - - - - Fee cash flow margin (%) - - - - - Fee cash flow margin (%) - - - - - <t< td=""><td>3.6</td></t<>	3.6
Dividend yield (%) 5.6 4.6 3.8 6.8 3.6 EVKBITDA adj. (x) 8.1 5.8 8.1 1.7 13.9 EVKEITDA adj. (x) 8.1 5.8 8.1 1.7 13.9 EVKEITDA adj. (x) 8.1 5.8 8.1 1.7 13.9 EVKEITCA Adj. (x) - - - - - ROCE WAACC adj. (x) - - - - - ROCE WAACC adj. (x) - - - - - Sales growth (%) -15.0 78.8 -12.5 273.5 -75.1 EBITDA adj. margin (%) - - - - - At adj. margin (%) - - - - - Payout ratio (%) 42.0 25.0 29.3 11.3 49.9 Gearing (%) (net debulceuity) 8.2 7.4 6.6 2.2 2.0 Net adbutEBITDA (x) 0.8 0.5 0.5 0.1 0.3 <td>3.7</td>	3.7
EV/Sales (x) - <t< td=""><td>0.0</td></t<>	0.0
EV/EBITDA adj. (x) 8.1 5.8 8.1 1.7 13.9 EV/EBIT adj. (x) 8.1 5.8 8.1 1.7 13.9 EV/CE (x) - - - - - ROCE/WACC adj. (x) - - - - - ROCE/WACC adj. (x) - - - - - Sales growth (%) -15.0 78.8 -12.5 273.5 -75.1 EBIT Adj. margin (%) - - - - - - Reat adj. margin (%) -	-
EV/EBIT adj. (x) 8.1 5.8 8.1 1.7 13.9 EV/CE (x) -	8.6
EV/CE (x) -	8.6
ROCE WACC adj. (x) - - - - - . Key company dat - <	0.0
Key company data Sales growth (%) - <t< td=""><td></td></t<>	
Sales growth (%) .	-
EBITDA adj. growth (%) -15.0 78.8 -12.5 273.5 -75.1 EBITDA adj. margin (%) - <td></td>	
EBITDA adj. margin (%) - - - - - IEBIT adj. margin (%) - - - - - - Net adj. margin (%) - - - - - - Preo cash flow margin (%) - - - - - - Payout ratio (%) 42.0 25.0 29.3 11.3 49.9 Gearing (%) (net debl/equity) 8.2 7.4 6.6 2.2 2.0 Net debl/EBITDA (x) 0.8 0.5 0.5 0.1 0.3 Equity ratio (x) (equity/total assets) 91.9 92.7 93.3 95.4 95.8 Capital employed (CHF mn) 0.0 0.0 0.0 0.0 0.0 0.0 ROCE adj. (%) - - - - - - - Turnover 0.0 1.25	62.0
EBIT adj. margin (%) - - - - - Free cash flow margin (%) - <td>02.0</td>	02.0
Net adj. margin (%) -	
Free cash flow margin (%) - <td></td>	
Payout ratio (%) 42.0 25.0 29.3 11.3 49.9 Gearing (%) (net debt/equity) 8.2 7.4 6.6 2.2 2.0 Net debt/EBITDA (x) 0.8 0.5 0.5 0.1 0.3 Equity ratio (x) (equity/total assets) 91.9 92.7 93.3 95.4 95.8 Capital employed (CHF mn) 0.0 0.0 0.0 0.0 0.0 0.0 ROCE adj. (%) - - - - - - - Immover 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EBITDA 118.3 211.5 185.1 691.5 172.5 EBIT 118.3 211.5 185.1 691.5 172.5 EBIT daj. 118.3 211.5 185.1 691.5 172.5 EBIT daj. 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 <td>-</td>	-
Gearing (%) (net debt/equity) 8.2 7.4 6.6 2.2 2.0 Net debt/EBITDA (x) 0.8 0.5 0.5 0.1 0.3 Equity ratio (x) (equity/total assets) 91.9 92.7 93.3 95.4 95.8 Capital employed (CHF mn) 0.0 0.0 0.0 0.0 0.0 0.0 ROCE adj. (%) - - - - - - Income statement (CHF mn) 0.0 0.0 0.0 0.0 0.0 0.0 EBITDA 118.3 211.5 185.1 691.5 172.5 EBIT Adj. 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 <t< td=""><td>-</td></t<>	-
Net deb//EBITDA (x) 0.8 0.5 0.5 0.1 0.3 Equity ratio (x) (equity/total assets) 91.9 92.7 93.3 95.4 95.8 Capital employed (CHF mn) 0.0 0.0 0.0 0.0 0.0 RCE adj. (%) - - - - - Income statement (CHF mn) 0.0 0.0 0.0 0.0 0.0 Turnover 0.0 0.0 0.0 0.0 0.0 0.0 EBITDA 118.3 211.5 185.1 691.5 172.5 EBIT Adj. 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) -	0.0
Equity ratio (x) (equity/total assets)91.992.793.395.495.8Capital employed (CHF mn)0.00.00.00.00.0ROCE adj. (%)Turnover0.00.00.00.00.0BBITDA118.3211.5185.1691.5172.5EBITDA adj.118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT115.9209.1182.7690.4171.4Net profit after minorities115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Balance sheet (CHF mn)Non-current assets1,2541,4171,5462,2102,406thereof goodwillCurrent assets75667Total assets1,2601,4221,5522,2162,413Shareholders' equity1,1581,3181,4492,1142,311	1.7
Capital employed (CHF mn) 0.0 0.0 0.0 0.0 0.0 ROCE adj. (%) -	0.2
ROCE adj. (%) - <	96.3
Income statement (CHF mn) Turnover 0.0 0.0 0.0 0.0 0.0 EBITDA 118.3 211.5 185.1 691.5 172.5 EBITDA adj. 118.3 211.5 185.1 691.5 172.5 EBIT 118.3 211.5 185.1 691.5 172.5 EBIT 118.3 211.5 185.1 691.5 172.5 EBIT 118.3 211.5 185.1 691.5 172.5 EBIT adj. 118.3 211.5 185.1 691.5 172.5 EBT 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - - - - - - - - - - -	0.0
Turnover0.00.00.00.00.0EBITDA118.3211.5185.1691.5172.5EBITDA adj.118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT adj.118.3211.5185.1691.5172.5EBT115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Balance sheet (CHF mn)115.9209.1182.7690.4171.4Non-current assets1,2541,4171,5462,2102,406thereof goodwillCurrent assets1,2601,4221,5522,2162,413Shareholders' equity1,1581,3181,4492,1142,311Total equity and liabilities1,2601,4221,5522,2162,413	-
EBITDA118.3211.5185.1691.5172.5EBITDA adj.118.3211.5185.1691.5172.5EBIT118.3211.5185.1691.5172.5EBIT adj.118.3211.5185.1691.5172.5EBT115.9209.1182.7690.4171.4Net profit after minorities115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Net profit adj.115.9209.1182.7690.4171.4Deformer assets1,2541,4171,5462,2102,406thereof goodwillCurrent assets75667Total assets1,2601,4221,5522,2162,413Shareholders' equity1,1581,3181,4492,1142,311Total equity and liabilities1,2601,4221,5522,2162,413	
EBITDA adj. 118.3 211.5 185.1 691.5 172.5 EBIT 118.3 211.5 185.1 691.5 172.5 EBIT adj. 118.3 211.5 185.1 691.5 172.5 EBT adj. 118.3 211.5 185.1 691.5 172.5 EBT adj. 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) - - - - - - Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - Current assets 1	0.0
EBIT 118.3 211.5 185.1 691.5 172.5 EBIT adj. 118.3 211.5 185.1 691.5 172.5 EBT 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) 115.9 209.1 182.7 690.4 171.4 Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - Current assets 7 5 6 6 7 - Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity and liabilities 1,260 1,422 1,552 2,216 2,413	279.5
EBIT adj. 118.3 211.5 185.1 691.5 172.5 EBT 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) 115.9 209.1 182.7 690.4 171.4 Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - Current assets 7 5 6 6 7 Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity and liabilities 1,260 1,422 1,552 2,216 2,413	279.5
EBT 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) Von-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - <	279.5
Net profit after minorities 115.9 209.1 182.7 690.4 171.4 Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) - - 690.4 171.4 Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - Current assets 7 5 6 6 7 Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	279.5
Net profit adj. 115.9 209.1 182.7 690.4 171.4 Balance sheet (CHF mn) Von-current assets 1,254 1,417 1,546 2,210 2,406 Ithereof goodwill - - - - - - Current assets 7 5 6 6 7 Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	278.3
Balance sheet (CHF mn) Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill - - - - - - Current assets 7 5 6 6 7 Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	278.3
Non-current assets 1,254 1,417 1,546 2,210 2,406 thereof goodwill -	278.3
thereof goodwill -	
Current assets 7 5 6 6 7 Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	2,711
Total assets 1,260 1,422 1,552 2,216 2,413 Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	-
Shareholders' equity 1,158 1,318 1,449 2,114 2,311 Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	7
Total equity and liabilities 1,260 1,422 1,552 2,216 2,413	2,718
	2,616
Net debt 95 97 96 46 45	2,718
	45
Cash flow (CHF mn)	
Cash flow from operations -3.1 -2.9 -4.2 -3.5 -3.5	-3.5
of which change in working capital 0.0 0.0 0.0 0.0 0.0	0.0
Cash flow from investments 60.0 52.0 60.0 58.6 83.2	90.5
of which investment in fixed assets 0.0 0.0 0.0 0.0	0.0
Free cash flow 56.9 49.1 55.8 55.1 79.7	87.0
Dividends paid -40.8 -48.7 -52.2 -53.6 -78.2	-85.5
Cash flow from financing activities -56.4 -51.0 -54.5 -54.7 -79.4	-86.7
Change in cash position 0.4 -1.8 1.4 0.4 0.4	0.4

Source: Company data, Baader Helvea Equity Research

BAADER

Baader Helvea Equity Research COMPANY FLASH



HBM Healthcare Investments

Disclaimer

Baader Bank AG, Weihenstephaner Strasse 4, 85716 Unterschleissheim, Germany Baader Helvea AG, Talstrasse 9, 8001 Zurich, Switzerland Baader Helvea Limited, 5 Royal Exchange Buildings, London EC3V 3NL, United Kingdom

Baader Bank AG is the parent company of Baader Helvea AG and/or Baader Helvea Limited. Baader Bank AG, Baader Helvea AG and Baader Helvea Limited are collectively referred to as **"Baader Helvea Group Europe Companies"** below, and each of them is referred to separately as a **"Baader Helvea Group Europe Company"**. Baader Bank AG and its subsidiaries and affiliates, including Baader Helvea AG and Baader Helvea Limited, are collectively referred to below as the **"Group Companies"**.

The information set forth in this document has been diligently compiled by Baader Bank AG and is partially based on publicly available sources and data supplied by third parties (including data supplied by AlphaValue S.A., a cooperation partner of Baader Bank AG) believed to be reliable. Baader Bank AG does not warrant the accuracy or completeness of such information.

All estimates and opinions included herein represent the independent judgment of the analyst(s) named in the Research Document as of the date of publication of this Research Document.

This Research Document was completed at 11:31 AM (CEST) on 26-07-2021.

The relevant Baader Helvea Group Europe Company reserves the right to modify the views expressed herein at any time without notice and the right not to update this information and to discontinue coverage of the company that is the subject of this Research Document without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. Neither the Group Companies, any of their authorized representatives or employees nor any other person accepts any liability whatsoever for any loss arising from any use of this Research Document or its contents or otherwise arising in connection therewith.

Please note the information on the preparation of this document, the important notice, the advice regarding possible conflicts of interests, and the mandatory information required by Art. 20 of the Regulation (EU) No 596/2014 of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 and pursuant to Art. 34, 36 and 37 of the Commission Delegated Regulation (EU) No 2017/565 of 25 April 2016 and other applicable rules under http://www.baaderbank.de/disclaimer_research.html.

Baader Bank AG is a stock corporation (*Aktiengesellschaft*) organized under the laws of the Federal Republic of Germany with its principal place of business in Unterschleissheim. It is registered with the District Court (*Amtsgericht*) in Munich under No. HRB 121537 and supervised by the German Financial Supervisory Authority (*Bundesanstalt für Finanzdienstleistungsaufsicht – BaFin*), Marie-Curie-Strasse 24-28, 60439 Frankfurt am Main and Graurheindorfer Strasse 108, 53117 Bonn. The value added tax identification number of Baader Bank AG is DE 114123893.

A list of all of our Research Documents on any financial instrument or issuer that were disseminated during the preceding 12-month period is available to our clients under http://www.baaderbank.de/disclaimer_research.html.

Research Documents with recommendation changes (rating or target price) published in the twelve months prior to the publication of this Research Document covering the same financial instruments or issuers.

Company	Date	Rating	Currency	/ Target price	Closing pric	e as of	Analyst
HBM Healthcare Investment	s 01-Mar-21	Add	CHF	355.00	325.00	26-Feb-21	Bruno Bulic, Ph.D.

Baader Helvea Equity Research COMPANY FLASH

HBM Healthcare Investments

Contacts

Markus Mayer Head of Research +49 89 5150 1818 markus.mayer@baaderbank.de

EQUITY RESEARCH

Capital Goods Capital Goods (Switzerland) Capital Goods (Switzerland) Capital Goods Capital Goods (Germany)	Rolf Renders Emrah Basic Christian Obst, CEFA Peter Rothenaicher	+41 43 388 9213 +41 43 388 9250 +49 89 5150 1805 +49 89 5150 1817	rrenders@helvea.com ebasic@helvea.com christian.obst@baaderbank.de peter.rothenaicher@baaderbank.de	
Chemicals	Markus Mayer	+49 89 5150 1818	markus.mayer@baaderbank.de	
Consumer Consumer Durables / Food Retail / Non Food Retail Food & Beverages	Volker Bosse, CEFA Co-Head Equity Research Andreas von Arx Head of Swiss Equity Research	+49 89 5150 1815 +41 43 388 9257	volker.bosse@baaderbank.de avonarx@helvea.com	
Financial Services	Tim Dawson Andreas von Arx	+41 43 388 9232 +41 43 388 9257	tdawson@helvea.com avonarx@helvea.com	
Metals & Mining	Christian Obst, CEFA	+49 89 5150 1805	christian.obst@baaderbank.de	
Pharma	Bruno Bulic, Ph.D.	+41 43 388 9225	bbulic@helvea.com	
Real Estate	Andre Remke, CFA Co-Head Equity Research Andreas von Arx	+49 89 5150 1816 +41 43 388 9257	andre.remke@baaderbank.de avonarx@helvea.com	
Technology Software / IT Services / Support Services	Knut Woller, CEFA	+49 89 5150 1807	knut.woller@baaderbank.de	
Transport	Christian Obst, CEFA	+49 89 5150 1805	christian.obst@baaderbank.de	
EQUITY STRATEGY	Gerhard Schwarz, CEFA Head of Equity Strategy	+49 89 5150 1812	gerhard.schwarz@baaderbank.de	
EQUITY SALES Frankfurt +49 69 1388 1357 London +44 20 7054 7100	DERIVATIVES SALES Munich +49 89 5150 1990	EQUITY SALES TRADING Frankfurt +49 69 1388 1354 London +44 20 7054 7100	5	

Munich

Zurich

New York

+49 89 5150 1870

+1 212 935 5150

+41 43 388 9200

For North American clients:New York+1 212 935 5150

+49 89 5150 1850

+41 43 388 9200

Munich

Zurich

PUBLICATION ADDRESSES Baader Bank AG Equity Research Weihenstephaner Strasse 4 85716 Unterschleissheim, Germany

T +49 89 5150 1810

Baader Helvea AG Equity Research Talstrasse 9 8001 Zurich, Switzerland

T +41 43 388 9250



